IP Library Granted Patent US 12,110,493
Granted Patent B2
US 12,110,493 · App. 17/490,215 · Granted Oct 8, 2024

Engineered purine nucleoside phosphorylase variant enzymes

Inventors: Scott J. Novick (Palo Alto, CA); Nikki Dellas (San Carlos, CA); Vesna Mitchell (Santa Clara, CA); Da Duan (Newark, CA); Jovana Nazor (Milpitas, CA); Oscar Alvizo (Fremont, CA); Auric Anthony Sowell-Kantz (Mill Valley, CA); Jeffrey C. Moore (Westfield, NJ); Mark A. Huffman (Rahway, NJ); Agustina Rodriguez-Granillo (Rahway, NJ); Deeptak Verma (Rahway, NJ); Nicholas M. Marshall (Rahway, NJ); Jay H. Russell (Rahway, NJ); Keith A. Canada (Freehold, NJ)
Assignee: Codexis, Inc.
C12N15/63C12Y204/02001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,110,493
App. No.
17/490,215
Granted
Oct 8, 2024
Kind
B2
Abstract

The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Claims (11)

1. A polynucleotide sequence encoding an engineered purine nucleoside phosphorylase comprising a polypeptide sequence having at least 85% sequence identity to SEQ ID NO:2, wherein the polypeptide sequence of said engineered purine nucleoside phosphorylase comprises a substitution at position 65 and wherein the polypeptide sequence is numbered with reference to SEQ ID NO: 2, and wherein said engineered purine nucleoside phosphorylase comprises improved activity on compound 3

as compared to wild-type E. coli purine nucleoside phosphorylase.

2. The polynucleotide sequence of claim 1 , wherein said polynucleotide sequence is operably linked to a control sequence.

3. The polynucleotide sequence of claim 1 , wherein said polynucleotide sequence is codon optimized.

4. The polynucleotide sequence of claim 1 , wherein said polynucleotide sequence comprises the polynucleotide sequence as set forth in SEQ ID NO: 5.

5. An expression vector comprising the polynucleotide sequence of claim 1 .

6. A host cell comprising the expression vector of claim 5 .

7. A host cell comprising the polynucleotide sequence of claim 1 .

8. A method of producing an engineered purine nucleoside phosphorylase in a host cell, comprising culturing the host cell of claim 7 , under suitable conditions, such that the engineered purine nucleoside phosphorylase is produced.

9. The method of claim 8 , further comprising recovering the engineered purine nucleoside phosphorylase from the culture and/or host cell.

10. The method of claim 9 , further comprising a step of purifying said engineered purine nucleoside phosphorylase.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (4)
Division 16460025 · Jul 2, 2019
Provisional Application 62695507 · Jul 9, 2018
Provisional Application 62822263 · Mar 22, 2019
Related Publication 20220010316A1 · Jan 13, 2022